N/A
N=109
Tobacco Dependence Treatment for Asian Americans
Tobacco Dependence
Bottom Line
View on ClinicalTrials.gov: NCT01091363 ↗Enrolled (actual)
109
Serious AEs
4.6%
Results posted
Mar 2019
Primary outcome: Primary: 12-month Abstinence — 21; 6 Participants — p=<0.01
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Standard (Behavioral); Deep Cultural (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Massachusetts, Boston
- Primary completion
- Sep 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY 12-month Abstinence |
21; 6 | <0.01 sig |
| SECONDARY Perceived Family Norm Toward Quitting Smoking |
5.14; 4.81 | 0.02 sig |
Summary
Nicotine dependence is very common among Asian Americans; yet, research on understanding and treating nicotine dependence in this group is almost nonexistent. The proposed study is a first attempt to develop a smoking cessation program that is tailored to Korean-culture specific aspects. It is proposed that Korean Americans who receive a culturally tailored smoking cessation program will be more likely to have prolonged abstinence at 12-month follow-up than their counterparts who receive brief cessation counseling. Subjects in both arms receive nicotine patches for 8 weeks. Self-reported abstinence is validated with exhaled carbon monoxide and salivary cotinine tests.
Eligibility Criteria
Inclusion Criteria
Korean-speaking Koreans who:
- Are ages of 18 and older
- Have been smoking at least 10 or more cigarettes on average per day for the past 30 days; AND
- Are willing to quit smoking and receive NRT
Exclusion Criteria
- Inability to speak and understand Korean or English
- Involvement in behavioral or other pharmacological smoking cessation programs
- History of serious cardiac diseases and/or presence of skin diseases (see Human Subjects); OR
- Pregnancy, lactation or plans to become pregnant in the next 12 months
Data sourced from ClinicalTrials.gov (NCT01091363). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.